Different countries set prices based on a range of factors—list prices, rebates, negotiated discounts, GDP adjustments, or health-technology assessments—making direct comparisons unreliable. HHS clarified MFN applies only to single-source brand-name drugs without generic competition, further restricting and complicating comparisons. Qui-tam risk for overbilling.